TMEDT. Rowe Price Health Care ETF
Seeks long-term capital appreciation.
By T. Rowe Price · Launched 2025
Annual Cost
0.44%
#2,133 of 5,861 · average
Fund Size
$23M
#4,362 of 5,861 · small
Return (1Y)Goal
+38.6%
Track Record
1 year
#4,359 of 5,861 · young
Performance
Total-return NAV · USDGrowth of $10,000
$14,176+41.8%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Active selection
Factor
Multifactor
Sector
Health careFocus
Biotech & Genomics
Index tracked
MSCI GICS Health Care sector
What it actually holds
By weightConcentration
Top 10 holdings = 44.6% of fundmoderately concentrated
ELI LILLY & CO
14.5%
UNITEDHEALTH GROUP INC
6.5%
THERMO FISHER SCIENTIFIC INC
4.6%
GILEAD SCIENCES INC
4.1%
ABBOTT LABORATORIES
3.9%
DANAHER CORP
2.7%
MEDTRONIC PLC
2.2%
ALNYLAM PHARMACEUTICALS INC
2.1%
STRYKER CORP
2.0%
DYNE THERAPEUTICS INC
1.9%
Asset allocation
Stocks
99.3%
Cash
0.7%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
18.4%Moderate
Year-on-year price swings
Max drawdown
-11.1%Mild
Worst peak-to-trough loss
Sharpe (3Y)
Unavailable
Needs 3+ years of history
Sortino (3Y)
Not yet
Needs 3+ years of history
Listing
- Exchange
- NASDAQ Global Select Market
Full fund details
- Objective
- Seeks long-term capital appreciation.
- Strategy
- Invests primarily in securities of health care companies, including pharmaceuticals and biotechnology, with at least 80% of net assets in this sector. Uses fundamental analysis and may invest in companies of any market capitalization, focusing on U.S. common stocks but may include foreign stocks.
- Inception date
- June 11, 2025
- Fund family
- T. Rowe Price
Similar funds
Same asset class, closest by strategy & exposureWhat's next?
You've looked at TMED. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-04